A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Condition: Gastrointestinal Stromal Tumors
MeSH terms: Gastrointestinal Stromal Tumors
Intervention: Ripretinib; Sunitinib
Intervention description: Oral KIT/PDGFRA kinase inhibitor; Oral receptor tyrosine kinase (RTK) inhibitor
Intervention MeSH terms: Sunitinib
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 453.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This is a 2-arm, randomized, open-label, international, multicenter study comparing the
      efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to
      first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized
      in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or
      sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).
    

Eligibility criteria:

        Inclusion Criteria:

          1. Patients ≥ 18 years of age at the time of informed consent.

          2. Histologic diagnosis of GIST and must be able to provide an archival tumor tissue
             sample, otherwise, a fresh biopsy is required.

          3. Molecular pathology report must be available. If molecular pathology report is not
             available or insufficient, an archival tumor tissue sample or fresh biopsy is required
             for mutation status confirmation by the central laboratory prior to randomization.

          4. Patients must have progressed on imatinib or have documented intolerance to imatinib.

          5. Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of ≤ 2 at screening.

          6. Female patients of childbearing potential must have a negative serum beta-human
             chorionic gonadotropin (β-hCG) pregnancy test at screening and negative pregnancy test
             at Cycle 1 Day 1 prior to the first dose of study drug.

          7. Patients of reproductive potential must agree to follow the contraception requirements
             outlined in the study protocol.

          8. Patients must have at least 1 measurable lesion according to Modified Response
             Evaluation Criteria in Solid Tumors (mRECIST) Version 1.1 (non nodal lesions must be ≥
             1.0 cm in the long axis or ≥ double the slice thickness in the long axis) within 21
             days prior to the first dose of study drug.

          9. Adequate organ function and bone marrow reserve as indicated by the central laboratory
             assessments performed at screening.

         10. Resolution of all toxicities from prior therapy to ≤ Grade 1 (or patient baseline)
             within 1 week prior to the first dose of study drug (excluding alopecia and ≤ Grade 3
             clinically asymptomatic lipase, amylase, and creatine phosphokinase laboratory
             abnormalities).

         11. The patient is capable of understanding and complying with the protocol and the
             patient has signed the informed consent document. Signed informed consent form (ICF)
             must be obtained before any study-specific procedures are performed and the patient
             must agree to not participate in any other interventional clinical trial while on
             treatment in this clinical trial. Participation in a noninterventional study
             (including observational studies) is permitted.

        Exclusion Criteria:

          1. Treatment with any other line of therapy in addition to imatinib for advanced GIST.
             Imatinib-containing combination therapy in the first-line setting is not allowed.

          2. Patients with a prior or concurrent malignancy whose natural history or treatment have
             the potential to interfere with the safety or efficacy assessment of this clinical
             trial are not eligible.

          3. Patient has known active central nervous system metastases.

          4. New York Heart Association class II-IV heart disease, myocardial infarction within 6
             months of cycle 1 day 1, active ischemia or any other uncontrolled cardiac condition
             such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy,
             uncontrolled hypertension or congestive heart failure.

          5. Left ventricular ejection fraction (LVEF) < 50% at screening.

          6. Arterial thrombotic or embolic events such as cerebrovascular accident (including
             ischemic attacks) or hemoptysis within 6 months before the first dose of study drug.

          7. Venous thrombotic events (e.g. deep vein thrombosis) or pulmonary arterial events
             (e.g. pulmonary embolism) within 1 month before the first dose of study drug. Patients
             on stable anticoagulation therapy for at least one month are eligible.

          8. 12-lead ECG demonstrating QT interval corrected (QTc) by Fridericia's formula > 450 ms
             in males or > 470 ms in females at screening or history of long QTc syndrome

          9. Use of known substrates or inhibitors of breast cancer resistance protein (BCRP)
             transporters within 14 days or 5 x the half-life (whichever is longer) prior to the
             first dose of study drug.

         10. Major surgeries (e.g. abdominal laparotomy) within 4 weeks of the first dose of study
             drug. All major surgical wounds must be healed and free of infection or dehiscence
             before the first dose of study drug.

         11. Any other clinically significant comorbidities.

         12. Known human immunodeficiency virus or hepatitis C infection only if the patient is
             taking medications that are excluded per protocol, active hepatitis B, or active
             hepatitis C infection.

         13. If female, the patient is pregnant or lactating.

         14. Known allergy or hypersensitivity to any component of the study drug.

         15. Gastrointestinal abnormalities including but not limited to:

               -  inability to take oral medication

               -  malabsorption syndromes

               -  requirement for intravenous (IV) alimentation

         16. Any active bleeding excluding hemorrhoidal or gum bleeding.